AmEx Pharmacy Bevacizumab Syringes Recall: Lack of Sterility Assurance
AmEx Pharmacy recalls Bevacizumab 2.5 mg/0:1 mL syringes due to lack of sterility assurance. All remaining lots within expiry date are affected.
Recall notice
Lack of assurance of sterility.
Contact the company
What happened, in plain English
AmEx Pharmacy is recalling Bevacizumab 2.5 mg/0.1 mL intravitreal syringes because they may not be sterile. This could lead to infections if used improperly. Read more at govinfonow.com/recall/38060-amex-pharmacy-bevacizumab-syringes-recall-lack-of-sterility-assurance.
Source Summary by GovInfoNow · govinfonow.com/recall/38060-amex-pharmacy-bevacizumab-syringes-recall-lack-of-sterility-assurance · Updated October 5, 2026 · FDA enforcement record: FDA #D-1849-2019
Cite this page
“AmEx Pharmacy Bevacizumab Syringes Recall: Lack of Sterility Assurance.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/38060-amex-pharmacy-bevacizumab-syringes-recall-lack-of-sterility-assurance. Based on FDA recall #D-1849-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1849-2019%22&limit=1).
Why it’s dangerous
The syringes lack assurance of sterility, meaning they might be contaminated with bacteria. If used, this could cause serious infections in the eye or body.
Who’s affected
Patients prescribed this medication by a doctor who received it from AmEx Pharmacy in Melbourne, Florida. Those with the specific syringe model and lot numbers are most at risk.
How to tell if you have this one
Check for the product name 'Bevacizumab, 2.5 mg/0.1 mL, Norm-Ject Syringe Intravitreal Injection' and the label 'Repackaged by AmEx Pharmacy'. All lots within expiry date are affected.
- Brand
AmEx Pharmacy- Category
Drug
All 2 products in this recall
FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.
- Classification
Class II- Status
Terminated- Distribution
Continental U.S. and Puerto Rico
| Recall number | Product, codes & lots | Quantity |
|---|---|---|
| D-1849-2019 | Bevacizumab, 2.5 mg/0.1 mL, Norm-Ject Syringe Intravitreal Injection, Single use only, Rx only, Repackaged by AmEx Pharmacy 1515 Elizabeth St. Suite J Melbourne, FL 32901; All lots remaining within expiry. | — |
| D-1850-2019 | Bevacizumab, 1.25 mg/0.05 mL, 31G MJ Syringe Intravitreal Injection, Single use only, Rx only, Repackaged by AmEx Pharmacy 1515 Elizabeth St. Suite J Melbourne, FL 32901; All lots remaining within expiry. | — |
What to do — step by step
Check Product Details
Look for the product name and 'Repackaged by AmEx Pharmacy' on the syringe label.
Where it went and when
Where it was distributed
Distributed in Puerto Rico.
FDA distribution: “Continental U.S. and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Puerto Rico.
Recall timeline
FDA terminated this recall 13 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1849-2019 (August 30, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1849-2019 to see it in context.
- Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.